Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment

Digestive Diseases and Sciences

Volumn 53, Issue 11, 2008, Pages 2995-2998

  Ozaras, Resat ^a   Tabak, Fehmi ^a   Tahan, Veysel ^b   Ozturk, Recep ^a   Akin, Hakan ^b   Mert, Ali ^a   Senturk, Hakan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Automated chemiluminescent microparticle immunoassay; Chronic hepatitis B; HBsAg quantitation

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; PLACEBO; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOASSAY; INTERFERON ALFA-2B; LAMIVUDINE; MALE; VIRAL LOAD;

EID: 53849141188     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0263-5     Document Type: Article

References (18)

1. S Bowden 2006 Serological and molecular diagnosis Semin Liver Dis 26 97 103
2. A Hatzakis E Magiorkinis C Haida 2006 HBV virological assessment J Hepatol 44 1 Suppl S71 S76
3. JC Servoss LS Friedman 2004 Serologic and molecular diagnosis of hepatitis B virus Clin Liver Dis 8 267 281
4. RP Perrillo ER Schiff GL Davis HC Bodenheimer Jr K Lindsay J Payne JL Dienstag C O'Brien C Tamburro IM Jacobson 1990 A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med 323 295 301
5. DK Wong AM Cheung K O'Rourke CD Naylor AS Detsky J Heathcote 1993 Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 312 323
6. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman L Crowther LD Condreay M Woessner M Rubin NA Brown 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256 1263
7. AB van Nunen BE Hansen DJ Suh HF Löhr L Chemello H Fontaine J Heathcote BC Song HL Janssen RA de Man SW Schalm 2003 Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 420 424
8. J Feld JY Lee S Locarnini 2003 New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B Hepatology 38 545 553
9. HLA Janssen M van Zonneveld H Senturk S Zeuzem US Akarca Y Cakaloglu C Simon TMK So G Gerken RA de Man HGM Niesters P Zondervan B Hansen SW Schalm HBV 99-01 Study Group; Rotterdam Foundation for Liver Research 2005 Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 123 129
10. MT Beard KA Edwards EL Curry DD Marshall MN Johnson 1996 Research methodology. Part IV: understanding canonical correlation analysis ABNF J 7 11 18
11. W Szmuness CE Stevens EA Zang EJ Harley A Kellner 1981 A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report Hepatology 1 377 385
12. M Deguchi N Yamashita M Kagita S Asari Y Iwatani T Tsuchida K Iinuma IK Mushahwar 2004 Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay J Virol Methods 115 217 222
13. CH Chen CM Lee JH Wang HD Tung CH Hung SN Lu 2004 Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers Eur J Gastroenterol Hepatol 16 1213 1218
14. R Gibb GR Nimmo P O'Loughlin P Lowe D Drummond 2007 Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection J Med Virol 79 351 355
15. H Scheiblauer H Soboll S Nick 2006 Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection J Med Virol 78 S66 S70
16. M Kohmoto M Enomoto A Tamori D Habu T Takeda N Kawada H Sakaguchi S Seki S Shiomi S Nishiguchi 2005 Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers J Med Virol 75 235 239
17. A Rodella C Galli L Terlenghi F Perandin C Bonfanti N Manca 2006 Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B J Clin Virol 37 206 212
18. HL Chan VW Wong AM Tse CH Tse AM Chim HY Chan GL Wong JJ Sung 2007 Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 1462 1468